TITLE:
Eruptive Lentigines after Adalimumab Therapy
AUTHORS:
Efstathia Pasmatzi, Alexandra Monastirli, Sophia Georgiou, Dionysios Tsambaos
KEYWORDS:
Lentigines, Melanocytes, TNF-α, Adalimumab, Psoriasis
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.5 No.4,
April
21,
2016
ABSTRACT: Adalimumab, a TNF-alpha antagonist, is the first fully humanized recombinant immunoglobulin G1 (IgG1) monoclonal antibody. It is presently widely used in the systemic treatment of rheumatoid arthritis, inflammatory bowel disease, moderate and severe psoriasis and hidradenitis suppurativa. However, its administration is associated with a two-fold risk of severe and possibly fatal infections and in some rare cases with congestive heart failure, lymphoma, lupus-like syndrome, cytopenias, hepatotoxicity and development of demyelinating neurological disorders. Furthermore, the occurrence of various types of melanocytic skin lesions has been reported during treatment with adalimumab. In the present paper we report the case of a female psoriatic patient who developed eruptive lentigines following treatment with this compound.